Barclays lowered the firm’s price target on Sangamo (SGMO) to $5 from $9 and keeps an Overweight rating on the shares. The company’s Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Sangamo Biosciences Announces $23 Million Share Offering
- Sangamo Biosciences: Strategic Financial Positioning and Regulatory Advancements Justify Buy Rating
- Sangamo Therapeutics Reports Q1 2025 Progress and Financials
- Sangamo reports Q1 EPS (14c) vs (27c) last year
- Sangamo backs FY25 operating expenses view $135M-$155M